Loxo Oncology, Inc. (LOXO) financial statements (2020 and earlier)

Company profile

Business Address 281 TRESSER BOULEVARD, 9TH FLOOR
STAMFORD, CT 06901
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:626142154106
Cash and cash equivalents142306844
Short-term investments4841098662
Other undisclosed cash, cash equivalents, and short-term investments 2  
Other undisclosed current assets156(0)31
Total current assets:782142157108
Noncurrent Assets
Property, plant and equipment1000
Long-term investments and receivables 2 7
Long-term investments 2 7
Deposits noncurrent assets   0
Other noncurrent assets111 
Total noncurrent assets:2417
TOTAL ASSETS:783145157114
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities271532
Accounts payable4100
Accrued liabilities231432
Deferred revenue and credits195   
Total current liabilities:2221532
Noncurrent Liabilities
Liabilities, other than long-term debt184   
Deferred revenue and credits184   
Total noncurrent liabilities:184   
Total liabilities:4051532
Stockholders' equity
Stockholders' equity attributable to parent378130155113
Common stock0000
Additional paid in capital667269221144
Accumulated other comprehensive loss(1)(0)(0)(0)
Accumulated deficit(288)(139)(67)(31)
Total stockholders' equity:378130155113
TOTAL LIABILITIES AND EQUITY:783145157114

Income statement (P&L) ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit: 0  
Operating expenses(174)(73)(24)(13)
Other undisclosed operating income (loss)21(0) (8)
Operating loss:(152)(73)(24)(21)
Loss from continuing operations before equity method investments, income taxes:(152)(73)(24)(21)
Other undisclosed income (loss) from continuing operations before income taxes 1(12)41
Income (loss) before gain (loss) on sale of properties:(152)(72)(36)21
Other undisclosed net income4   
Net income (loss):(149)(72)(36)21
Other undisclosed net income (loss) attributable to parent 00(41)
Net loss attributable to parent:(149)(72)(36)(21)
Preferred stock dividends and other adjustments   (0)
Net loss available to common stockholders, diluted:(149)(72)(36)(21)

Comprehensive Income ($ in millions)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(149)(72)(36)21
Comprehensive income (loss):(149)(72)(36)21
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(0)0(41)
Comprehensive loss, net of tax, attributable to parent:(149)(72)(36)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: